Evidence map›Paper›PMID 42825158›Full record

ArticleNeuro-oncology advances

Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma.

Nazanin Ijad, Katie L Waller, Erika Yamazawa, Naema Nayyar, Danielle Burgenske, Consuelo Torrini, Brett L Carlson, Elizabeth J Summers, Christian Migliarese, Braxton Marion and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nazanin IjadCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Katie L WallerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester.
Erika YamazawaCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Naema NayyarCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Danielle BurgenskeDepartment of Radiation Oncology, Mayo Clinic.
Consuelo TorriniCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.ORCID https://orcid.org/0000-0003-2743-0839
Brett L CarlsonDepartment of Radiation Oncology, Mayo Clinic.
Elizabeth J SummersCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Christian MigliareseDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston (C.M., H.W.).
Braxton MarionCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Britney Shela ZhangCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Emily SullivanCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Claudia EllingtonCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Varun SasisekharanCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
Paul A DeckerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester.ORCID https://orcid.org/0000-0002-3756-4227
Matthew KoselDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester.
Jeanette E Eckel-PassowDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester.ORCID https://orcid.org/0000-0002-6113-1114
Evanthia GalanisDepartment of Radiation Oncology, Mayo Clinic.ORCID https://orcid.org/0000-0001-8014-786X
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic.
Hiroaki WakimotoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston (C.M., H.W.).ORCID https://orcid.org/0000-0001-8225-241X
Rachael A VaubelDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester.ORCID https://orcid.org/0000-0001-8842-5975
Priscilla K BrastianosCenter for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.ORCID https://orcid.org/0000-0003-4470-8425

Funding

Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancerR01CA294793 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Priscilla Kaliopi Brastianos, LEIF W ELLISEN · 2024 to 2026
$3.5M
NCI NIH HHS R01 CA294793
6 · The paper itself

Abstract

Background: Meningiomas lack effective therapies for recurrent or aggressive disease. NF2 inactivation, commonly in meningioma, may sensitize tumors to FAK inhibition and interact with MAPK signaling. This study investigated the therapeutic activity of defactinib (FAK inhibitor) and avutometinib (RAF/MEK inhibitor) alone and in combination in preclinical meningioma models. Methods: MAPK-altered meningioma cell lines, IOMM-Lee ( Results: Conclusions: Avutometinib demonstrated robust anti-tumor effects in flank and intracranial models of MAPK-altered meningioma. Combination benefits were context dependent. Defactinib activity in

Indexed as

BRAF inhibitorcombination treatmentFAK inhibitorMEK inhibitormeningioma

Identifiers

PMID42825158
PMCPMC13629435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.